VE-821
ATR inhibitor / VE-821 is a potent and selective ATP-competitive ATR (Ataxia-telangiectasia and Rad3-related protein) inhibitor, Ki=13 nM.1 Increases the sensitivity of pancreatic2 and ovarian3 cancer cells to radiation and chemotherapy. Increased replication stress induced by PARP inhibitors or chemotherapeutic agents increases sensitivity to VE-821 in neuroblastoma cells.4 Enhances the cytotoxicity of DNA damaging agents.5
Biochemicals & reagents
1232410-49-9
1 Reaper et al. (2011), Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR; Nat. Chem. Biol., 7 428 2 Prevo et al. (2012), The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy; Cancer Biol. Ther., 13 1072 3 Huntoon et al. (2013), ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status; Cancer Res., 73 3683 4 King et al. (2021), Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells; Cancers (Basel), 13 6215 5 Moolmuang and Ruchirawat (2021), The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells; J. Pharm. Pharmacol., 73 40
-20°C
TARGET: Kinase; DNA -- PATHWAY: DNA damage; DNA repair; Cell cycle -- DISEASE AREA: Cancer